Asarina Pharma (Sweden)

Recent papers from Asarina Pharma (Sweden)

1. Golexanolone Attenuates Neuroinflammation, Fatigue, and Cognitive and Motor Impairment in Diverse Neuroinflammatory DisordersPharmaceuticals · 2025
2. Golexanolone Attenuates Neuroinflammation, Fatigue, and Cognitive and Motor Impairment in Diverse Neuroinflammatory DisordersPharmaceuticals · 2025
3. Golexanolone affords sustained improvement of Parkinson's symptoms in rats by reducing microglia activation that restores the glutamate-GABA-dopamine pathwayNeuropharmacology · 2025
4. Golexanolone affords sustained microglia and astrocytes activation improvement in a rat model of Parkinson’s diseaseFrontiers in Immunology · 2025
5. Potassium binders in clinical practice: understanding potassium binder use in contemporary Swedish healthcare—the DEMONSTRATE databaseBMC Nephrology · 2025
6. Z-score-based posttest risk as an alternative risk metric to positive predictive value following positive noninvasive prenatal screeningAmerican Journal of Obstetrics and Gynecology · 2024
7. Golexanolone reduces glial activation in the striatum and improves non-motor and some motor alterations in a rat model of Parkinson's diseaseFrontiers in Aging Neuroscience · 2024
8. Allopregnanolone and its antagonist modulate neuroinflammation and neurological impairmentNeuroscience & Biobehavioral Reviews · 2024
9. Neuroinflammation alters GABAergic neurotransmission in hyperammonemia and hepatic encephalopathy, leading to motor incoordination. Mechanisms and therapeutic implicationsFrontiers in Pharmacology · 2024
10. Golexanolone improves fatigue, motor incoordination and gait and memory in rats with bile duct ligationLiver International · 2023
11. Extra-Synaptic GABAA Receptor Potentiation and Neurosteroid-Induced Learning Deficits Are Inhibited by GR3027, a GABAA Modulating Steroid AntagonistBiomolecules · 2023
12. The GABA system, a new target for medications against cognitive impairment—Associated with neuroactive steroidsJournal of Internal Medicine · 2023
13. Apparent versus effective test performance: The importance of understanding and reviewing performance metricsPrenatal Diagnosis · 2023
14. Neurosteroid Activation of GABA-A Receptors: A Potential Treatment Target for Symptoms in Primary Biliary Cholangitis?Canadian Journal of Gastroenterology and Hepatology · 2022
15. Golexanolone, a GABAA receptor modulating steroid antagonist, restores motor coordination and cognitive function in hyperammonemic rats by dual effects on peripheral inflammation and neuroinflammationCNS Neuroscience & Therapeutics · 2022
16. A pilot study of golexanolone, a new GABA-A receptor-modulating steroid antagonist, in patients with covert hepatic encephalopathyJournal of Hepatology · 2021
17. Clinical and Budget Impact of Treating Preoperative Anemia in Major Orthopedic Surgery—A Retrospective Observational StudyThe Journal of Arthroplasty · 2020
18. Treatment of premenstrual dysphoric disorder with the GABAA receptor modulating steroid antagonist Sepranolone (UC1010)—A randomized controlled trialPsychoneuroendocrinology · 2017
19. Acceleration of Amyloidosis by Inflammation in the Amyloid-Beta Marmoset Monkey Model of Alzheimer’s DiseaseJournal of Alzheimer s Disease · 2016
20. GABAA receptor modulating steroid antagonists (GAMSA) are functional in vivoThe Journal of Steroid Biochemistry and Molecular Biology · 2015